PDCD1 and non-small cell lung carcinoma: However, given that camrelizumab was approved by NMPA as first-line treatment, but not second-line treatment for NSCLC patients, a high proportion of crossover to camrelizumab monotherapy may not reflect the real-world situation, where patients have to receive other more expensive PD-1/PD-L1 antibodies after progression (35).